BWC4496

BWC4496 is a small molecule inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), currently in preclinical development by Bugworks Research for the treatment of recalcitrant tumors. HPK1 is a member of the MAP4K family and acts as a negative regulator of T-cell, B-cell, and dendritic cell signaling. By inhibiting HPK1, BWC4496 is designed to enhance T-cell receptor (TCR) signaling and promote an active immune response against cancer cells. This mechanism aims to reverse the immunosuppressive environment often found in advanced or recalcitrant tumors, potentially improving the efficacy of existing immunotherapies or serving as a potent monotherapy.